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The authors describe the case of a young woman who developed a clinical pictures resembling a septic shock-relatedmultiple organ
dysfunction syndrome a couple of months after having been diagnosed suffering from a hemophagocytic lymphohistiocytosis
associated with an infectious mononucleosis. Despite the aggressive treatment, which included antibiotics, vasopressors, IV
immunoglobulins, and the use of an extracorporeal device aimed to removemediators released both during sepsis and the cytokine
stormdetermined by the hemophagocytic lymphohistiocytosis, the patient died. At the autopsy, an extremely uncommon aggressive
lymphoma of Epstein-Barr virus-positive T-lymphocytes with systemic involvement was discovered.
1. Introduction.
Although most patients with infectious mononucleosis (IM)
recover without major clinical sequelae, a number of harmful
complications can occur, including hepatitis, splenic rupture,
and hematological abnormalities [1]; among the latter, the
hemophagocytic lymphohistiocytosis (HLH) is particularly
harmful because it is characterized by the massive pro-
duction and release of inflammatory mediators caused by
the uncontrolled activation of T-lymphocytes, NK-cells, and
macrophages; the ensuing clinical picture resembles septic
shock and can determine a multiple organ dysfunction syn-
drome (MODS) [2–4]. The HLH is increasingly recognized
in patients admitted to the Intensive Care Units (ICU) due to
different conditions including hematologic and solid tumors,
autoimmune diseases, and bacterial and viral infections. [4–
6]; as far IM-associated HLH is concerned, its occurrence
has been ascribed to the persistence of the Epstein-Barr virus
(EBV) in the tissues and the outcome is particularly poor [3].
Independently of the underlying triggering cause(s) the
differential diagnosis of secondary HLH is difficult and
relies mainly on a high index of suspicion and a number
of hematological and biochemical criteria basically derived
from those used in the pediatric form which is mostly caused
by genetic abnormalities [7], making their use less useful in
the acquired form (Table 1).
Here we describe the case of a patient who developed
a rapidly evolving MODS a couple of months after the
occurrence of an IM complicated by HLH.
2. Case Description
A 24-year-old woman was admitted to the Department
of Infectious Disease with fever (T = 38,3∘C) which was
attributed to a relapse of a IM-HLH occurring about two
months prior to the current hospitalization. At that time,
the diagnosis of IM was confirmed by the presence of
EBV DNA in the bloodstream and the diagnosis of HLH
was suspected on the basis of the clinical findings such as
persisting fever, the enlargement of the liver and the spleen
as well as of blood abnormalities including pancytopenia,
abnormally elevated values of ferritin (> 15.000 mcg/ml),
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Table 1: Diagnostic criteria of HLH.
Molecular diagnosis consistent with HLH.
Or 5 of the following criteria
(1) Fever
(2) Splenomegaly
(3) Cytopenia affecting ≥ 2 lineages
(a) Hemoglobin < 9g / dl
(b) Platelets < 90.000 / ml
(c) Neutrophils < 1000 /ml
(4) Hypertrigliceridemia and/or hypofibrinogemia
(a) Triglycerides > 265 mg/dl
(b) Fibrinogen < 150 mg/dl
(5) Hemophagocytosis in bone marrow, spleen or nodes
(6) Low/absent NK cell activity
(7) Ferritin ≥ 500 mcg/ml
(8) sCD25 (sIL2R) ≥ 2400U/ml
triglycerides (789 mg/dl), and liver enzymes (AST 175 U/L,
AST 120 U/L); a bone marrow biopsy confirmed the presence
of hemophagocytosis and viral RNA in many cells by means
of in situ hybridization (EBER) [7]; a genetic screening
excluded the presence of gene mutations associated with
HLH. During that hospitalization, she received steroids,
etoposide, rituximab, cyclosporine, granulocyte-stimulating
factor, and intravenous immunoglobulins (IvIg) and was
ultimately discharged 38 days after the initial admission
without viral DNA detectable in the bloodstream. During
her stay at home, which lasted 3 weeks, the patient received
prednisone, cyclosporine, trimethoprim-sulphametoxazole
and acyclovir through a peripherally inserted central venous
catheter (PICC).Thirty-six hours after the current admission
during which rituximab was added to the ongoing treatment
she was transferred to the ICU due to the deterioration of
the consciousness, arterial hypotension, and fever. At the
ICU admission, the patient presented high fever (40,5∘C),
disseminated intravascular coagulation, arterial hypotension,
and acute kidney injury requiring renal replacement therapy
(RRT): a methicillin-resistant Staph. aureus (MRSA) was
isolated from the blood cultures and a septic shock-related
MODS possibly in association with a cytokine storm caused
by the HLH were hypothesized; the patient was intubated
andmechanically ventilated and treated with IV vasopressors
at incremental doses, IV vancomycin, meropenem, and
caspofungin; the PICC was removed and replaced with a
central venous catheter; as the patient remained unresponsive
to the treatment, a Coupled Plasma Filtration andAdsorption
treatment (CPFA, LYNDA, Bellco, Mirandola, Italy) that
aimed at removing the inflammatory mediators was added to
the RTT along with the IV administration of IgM and IgA-
enriched IvIg (Pentaglobin, Biotest; Dreieich, Germany).
Despite this increasingly aggressive approach, the MODS
further worsened and the patient died 18 hours after the ICU
admission.
At the autopsy, the liver and the spleen appeared enlarged,
weighting 3110 g and 1230 g, respectively. Microscopically,
the spleen showed lymphocyte depletion and the scattered
necrosis of Malpighi’s follicles (Figure 1(a)) combined with
subversion of the general architecture due to a proliferation
of T-lymphocytes (CD3+) with predominant expression of
CD8 (Figure 1(b)). The lymphocyte population B (CD20+,
PAX-5+) was virtually absent, while there was a significant
increase in monocyte-macrophage component sometimes
associated with hemophagocytosis. The EBER highlighted
several lymphocytes with integrated EBV RNA in the nucleus
(Figure 1(c)). The liver showed several perivascular infil-
trates of polymorphic lymphocytes likewise those found in
the spleen and many monocyte-macrophage cells (CD14+,
CD64+). In the bonemarrow thereweremultiple lymphocyte
with polymorphic or abnormal nucleuses (Figure 2(a)) that
appeared to be almost exclusively CD8+ T-lymphocytes
(Figure 2(b)). Most of these cells were EBER positive (Fig-
ure 2(c)); B-lymphocytes (CD20+, PAX-5+) were almost
absent while there was an expansion of the monocyte-
macrophage series (CD14 +, CD64 +). The three hematopoi-
etic lines appeared contracted but with preserved maturation.
Mediastinal lymph nodes showed a diffuse proliferation
of medium/large sized lymphoid elements, sometimes with
single or multiple polymorphic nuclei (Figure 3(a)). The
lymphocyte population was composed by CD3+ CD8+ T-
lymphocytes with a limited presence of lymphocytes CD3+
CD4+ and absence of B cells (CD20 +, PAX-5 +).
3. Discussion
Different pathologic conditions, including macrophage acti-
vation syndrome (MAS), adult onset Still’s disease (AOSD),
catastrophic antiphospholipid syndrome (cAPS), and septic
shock share a similar clinical presentation characterized by
fever, arterial hypotension, andmultisystem involvement due
to the action of a number of inflammatory mediators [8].
This overlap of symptoms makes the diagnosis elusive and
the appropriate approach can be delayed in the absence of
other information. This difficulty is substantial because the
treatments differ widely among the various clinical entities:
as an example, in the AOSD, MAS, and CAPS, the adminis-
tration of immunosuppressant agents is warranted [6, 9] but
is strongly contraindicated in septic shock whose treatment
is based on the prompt administration of large-spectrum
antibiotics [10], which in many ICUs is combined with
the administration of eIg and the use of blood purification
techniques. This uncertainty can be particularly represented
in hematological patients, in whom the onset of MODS can
represent the final common pathway of different conditions,
including immunosuppression-related sepsis, the cytokine
release syndrome induced by novel cancer immunotherapies,
and HLH [8, 11, 12]. Moreover, the proposed diagnostic
criteria could not help in a critically ill patient, as none
of them is sensible and sensitive enough and/or they are
time-consuming: as an example, a recent study demonstrated
the even extremely elevated blood ferritin levels were not
predictive of LHL in adult patients [6]. Indeed, the described
patient lied in the grey area in which an inappropriate
approach means the difference between life and death. To
overcome the risks associated with a wrong diagnosis and
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(a) (b) (c)
Figure 1: (a) Spleen tissue (H&E 200x); (b) CD8 positive spleen lymphocytes (200x); (c) spleen EBV positive cells (EBER, 200x).
(a) (b) (c)
Figure 2: (a) Bone marrow pleomorphic lymphocytes (H&E 200x); (b) CD8 positive bone marrow lymphocytes (200x); (c) bone marrow
EBV positive lymphocytes (EBER, 200x).
(a) (b) (c)
Figure 3: (a) Mediastinal lymph node (H&E 200x); (b) CD8 positive lymph node lymphocytes (200x); (c) PAX-5 negative lymph node
lymphocytes (200x).
treatment we hypothesized that a septic shock was superim-
posed to a relapsed HLH and added to the already running
therapies the CPFA aiming to remove the inflammatory
mediators involved in both circumstances. Unfortunately,
also this approach failed to modify the fulminant clinical
course and the patient ultimately died. Moreover, it has
been hypothesized an increased virulence and/or a reduced
sensitivity to vancomycin in MRSA causing infections in
patients with solid or hematologic malignancies [13].
The autoptical findings demonstrated that the septic
shock occurred concomitantly with an aggressive lymphoma
with multiorgan involvement; actually, it is likely that long-
term treatment with immunosuppressant agents, albeit indi-
cated for the treatment of the HLH, may have determined
the evolution of the underlying chronic active EBV infec-
tion towards the aggressive T-cell lymphoma with systemic
involvement. This is an extremely uncommon finding, as
the tropism of EBV for B-lymphocyte has been associated
with B-cells cancers, including Burkitt, Hodgkin, and diffuse
large cell lymphomas [14, 15]; conversely EBV-positive T-cell
lymphoma is exceedingly uncommon in western populations
and has been attributed either to a possible antiapoptotic
action exerted by the viral DNA hosted in the infected T-
cells and/or to signals transmitted by some viral proteins
such as Latent Membrane Protein 1 causing the continuous
stimulation ofmembers of the TNF receptors [2, 16]. Actually,
it appears that in patients with EBV-related infections the
chronic persistence of an elevated viral load represents a risk
factor for HLH as well for other severe hematologic com-
plications, including disseminated intravascular coagulation
and lymphoma [2, 14]. In the described patient, however, viral
DNAwas absent at the discharge from the previous admission
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and this finding contrasts with the massive presence of EBV
in all tissues demonstrated at the autopsy. It is likely that the
immunosuppressant agents given to treat the HLH and to
prevent its relapse acted as a double-edged sword: from one
side they abated the hemophagocytosis, which was present
only marginally at the post mortem examination of the bone
marrow but from the other one triggered the reactivation of
the EBV and the rapidly developing lymphoma.
4. Conclusions
The occurrence of EBV infection-associated HLH and the
prevention of its relapse consists in the prolonged administra-
tion of immunosuppressant agents possibly associated with
bone-marrow transplantation. Similar to other conditions
associated with the decrease of the immune capabilities, this
treatment exposes the patients to infectious complications,
including viral reactivation and overwhelming bacterial
infections. The occurrence of aggressive hematologic cancers
is uncommon but must be kept into consideration in patients
with HLH admitted with conditions resembling septic shock.
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